By Professor Richard Bryan Lock

Conference Posters

Lock RB; Evans K; Watts B; Bowman EP; Neuhauser S; Stearns T; Chuang JH; Phillip VM; Jessen KA; Jocoy EL; Bult CJ; Teicher BA; Smith MA, 2024, 'Abstract 1905: The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia', Vol. 84, pp. 1905 - 1905, http://dx.doi.org/10.1158/1538-7445.am2024-1905

Cheung L; Lock R; Kuek V; Kotecha R, 2024, '3049 – TARGETING BONE MARROW MICROENVIRONMENT FOR TREATMENT OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', Vol. 137, pp. 104371 - 104371, http://dx.doi.org/10.1016/j.exphem.2024.104371

Cheung LC; Trinder S; Hughes A; Mullin B; Rashid S; Yuan J; Xu J; Duncan O; Lock RB; Malinge S; Kuek V; Kotecha RS, 2023, 'Targeting Bone Marrow Microenvironment for Treatment of High-Risk B-Cell Acute Lymphoblastic Leukemia', Vol. 142, pp. 2709 - 2709, http://dx.doi.org/10.1182/blood-2023-173503

Houghton PJ; Kurmasheva RT; Erickson S; Smith MA; Lock RB; Evans K; Toscan C, 2020, 'Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)', Vol. 138, pp. S18, http://dx.doi.org/10.1016/S0959-8049(20)31111-4

Karsa M; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Somers K; Henderson MJ, 2018, 'PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia', Vol. 3, pp. A181 - A181, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431

Back to profile page